{"id":"W596674826","doi":"10.1200/jco.2009.27.15_suppl.8504","title":"Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Refractory (planetary science); Lenalidomide; Internal medicine; Thalidomide; Bortezomib; Proteasome inhibitor; Phases of clinical research; Multiple myeloma; Gastroenterology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002010089,0.001603495,0.001455609,0.0003076653,0.0005307399,0.0007244038,0.0007164638,0.001237373,0.003903409],"category_scores_gemma":[0.0009055168,0.0004961998,0.0009749839,0.0002499116,0.000678386,0.0005289627,0.0003100011,0.002544857,0.001002567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009453925,"about_ca_system_score_gemma":0.001229572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001279239,"about_ca_topic_score_gemma":0.002255305,"domain_scores_codex":[0.9994966,0.0002500165,0.00002418392,0.00006544626,0.00004942867,0.000114254],"domain_scores_gemma":[0.9991742,0.0001570233,0.000125949,0.00005932643,0.00006572865,0.0004177702],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6119612,0.07379569,0.01858177,0.0008848269,0.001756307,0.000890689,0.0005832809,0.004870384,0.1321135,0.0004084873,0.01855568,0.1355982],"study_design_scores_gemma":[0.3673417,0.5547195,0.05339712,0.00005141787,0.0008265433,0.0006446968,0.00006772922,0.00177198,0.01298916,0.0003065066,0.007839785,0.00004385581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863085,0.001682612,0.001129858,0.0005074916,0.0001026906,0.003546294,0.00292265,0.0001467923,0.003653156],"genre_scores_gemma":[0.9824572,0.000834875,0.002145332,0.0009902886,0.0001502208,0.002062336,0.008011331,0.00005736089,0.003290946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003903409,"threshold_uncertainty_score":0.01305825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.235766069083282,"score_gpt":0.4884920284050808,"score_spread":0.2527259593217988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}